<DOC>
	<DOCNO>NCT02733068</DOCNO>
	<brief_summary>A Phase III Double Blinded , Randomized Controlled Study Evaluate Efficacy Protection Against HPV-16 18 Related Diseases , Immunogenicity Safety Recombinant Human Papillomavirus Virus-like Particle Vaccine ( Type 16 18 L1 Proteins , Yeast ) Healthy Females Aged 18-30 Years .</brief_summary>
	<brief_title>A Phase III Study Human Papillomavirus ( HPV ) -16/18 Vaccine .</brief_title>
	<detailed_description>This multi-centre , randomize , double blind , placebo control study . The study vaccine recombinant human papillomavirus bivalent ( type 16 18 ) vaccine ( Yeast ) , placebo aluminium phosphate diluent . This study plan enrol 12000 healthy female age 18-30 10 study site . Each participant receive three-dose schedule vaccine placebo randomly proportion control 1:1 vaccine group placebo group . After inoculation , immediate reaction observe 30 minute , local systemic reaction systematically observe 7 day . After first inoculation , adverse event collect one month final inoculation , serious adverse event collect 6 month final inoculation . Blood sample collect first inoculation , one month final injection , blood sample also collect group participant contain 800 people detect antibody titer . Follow-up visit conduct 14 time : month 0 , month 0 + 8 day , month 2 , month 2 + 8 day , month 6 , month 6 + 8 day , month 7 , month 12 , month 18 , month 24 , month 30 , month 36 , month 48 , month 60 . When cervical intraepithelial neoplasia grade 2+ ( CIN2+ ) indicate , participant receive standard treatment drop study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1830 healthy female enable provide legal identification ability understand sign Informed Consent Form confirm investigator participant ability comply protocol requirement agree use effective contraceptive method 7 month plan pregnancy avoid vaginal sex within two day ( 48 hour ) every interview ; n't employ vaginal douche intervention influence gynecological examination sample collection receive HPV vaccine previously ; receive research unregistered product ( drug vaccine ) within 30 day first injection within three month first injection , receive wholeblood , plasma immunoglobulin treatment , plan receive treatment research period ; within 28 day research , receive attenuated live vaccine ; within 14 day receive inactivated vaccine history allergic reaction require medical intervention ; allergic reaction vaccine vaccinecontaining element ; serious adverse effect history vaccine history epilepsy , convulsion family history mental disease immunodeficiency disease include : AIDS , HIV infection , lymphoma , leukemia , Systemic Lupus Erythematosus , rheumatoid arthritis , Juvenile Rheumatoid Arthritis , inflammatory bowel disease use immunosuppressor treatment corticosteroid drug systemic medication 6 month asplenia , functional asplenia , splenectomize liver kidney disease , serious cardiovascular disease , diabetes , history malignant tumor coagulation disorder menstrual period acute diseases pregnant , less 8 week delivery history sexual transmit disease total hysterectomy pelvic radiotherapy cervical abnormality abnormal screen result cervical cancer CIN two year accord judgement investigator , participant condition suitable trial planning move clinical trial site research period never vaginal sexual activity</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>